Align Technology Inc. (ALGN) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ALGN scores 66 out of 100, a C+ grade, with a verdict of "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:

• Fundamental Cash Engine: 14 / 20 (ROIC 11.1%; FCF yield 4.49%). This pillar indicates the business generates a moderate return on invested capital and a positive free-cash-flow yield, but not an exceptional one.
• Whale 13F Flow: 11 / 20 (institutional accumulation and options positioning). Institutional signals are only moderately supportive.
• Insider Conviction: 14 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signals are moderately constructive.
• Macro Regime Fit: 9 / 20 (Beta 0.9; sector sensitivity). This is the weakest pillar, suggesting the stock's fit with the prevailing macro regime is limited.
• Forensic Balance Sheet: 18 / 20 (Altman Z 4.62; Piotroski F 7/9; Debt/Equity 0.23). This is the strongest pillar, indicating the balance sheet is a clear source of resilience.

For a prospective investor evaluating the stock today, the rating points to a balanced picture: a strong balance sheet and a reasonable cash-generation profile offset weaker macro fit and only moderate institutional support. The "Watch for Breakout" language signals the rating's own framing that the score is near the middle of the range and would need a catalyst to move decisively. Valuation tradeoffs are visible in the market data: the P/E (TTM) of 26.6 and forward P/E of 24.7 sit at a premium relative to the FCF yield of 4.49%, so upside depends on earnings growth materializing. This is analytical context, not personalized advice.

Align Technology Inc. is listed on NASDAQ and classified under the Health Care sector and Industrial Specialties industry per the profile. Per the SEC financials and market data, the company reports a gross margin of 67.2%, an operating margin of 13.5%, and a net margin of 10.2%. The source data does not provide a detailed description of its products, customers, or specific revenue model.

Per the SEC financials, revenue rose from $3862.3M in FY 2023 to $4035.0M in FY 2025, while operating income and net income declined over the same period (operating income from $643.3M to $545.8M; net income from $445.0M to $410.0M). Per the Roarable RQD rating, the forensic balance sheet scores 18 out of 20, citing an Altman Z-Score of 4.62, a Piotroski F-Score of 7 of 9, and a Debt/Equity ratio of 0.23. Per the market data, ROIC is 11.1%. Reported debt declined from $1405.3M (FY 2023) to $983.0M (FY 2025).

• Risk Watch (multiple items): Headlines flagged RED/RISK WATCH include "3 Reasons ALGN is Risky and 1 Stock to Buy Instead," "Evercore ISI cuts Align Technology stock rating on weak demand," "Align Technology Shares Fall After Evercore ISI Downgrades Stock," and a "12-Month Price Target Cut to $185.85, Implies 21% Upside" report.
• Catalyst: "Align Technology: The Competitive Threat Has Eased, But Growth Remains A Concern" is flagged GREEN/CATALYST.
• Market Wire: "Align Technology Reports Q3 2026 Results, ALGN Stock Shows 31.6% Undervaluation on GF Value™" is flagged YELLOW/MARKET WIRE.
• Proprietary signals: The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

The news flow is predominantly risk-weighted (four RED items versus one GREEN and one YELLOW), with analyst downgrade and demand concerns as the recurring theme.

Per the Butterfly Supply-Chain Graph, the supply-chain classification is "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector-level context is the classification as Health Care / Industrial Specialties and the Beta of 0.9, which indicates the stock has historically tracked the broader market somewhat less than proportionally. Investors should monitor the demand-related commentary in the news wire as the most visible potential ripple.

• What is the specific cause of the reported weak demand cited in the Evercore ISI downgrade, and is it expected to persist?
• Why did operating and net income decline from FY 2023 to FY 2025 while revenue increased, and what drove the margin compression?
• What are the exact EPS figures by period, given that the financial source reports EPS as N/A for all three years?
• Who are the institutional and insider holders, and what is the direction of their recent activity?
• What is the full analyst consensus rating and price target distribution, beyond the single headline reference?